Nia Health

What Nia Health does

Nia Health GmbH is a Berlin-based digital health company founded in 2019 as a spin-off of Charité Universitätsmedizin Berlin, developing CE-approved medical device applications for chronic dermatological conditions. The company's core product portfolio comprises three indication-specific apps: Nia (atopic dermatitis/eczema, launched 2019), Sorea (psoriasis, launched 2020), and milderma (acne, launched 2023), each positioned as the first CE-marked medical device app in its respective indication. The underlying platform combines machine vision for automated skin image analysis and clinical scoring, natural language processing for symptom documentation, teledermatology workflows, and a remote patient monitoring module that integrates smartphone sensors and wearables for environmental trigger identification.

The company's technology stack is complemented by the ADEN platform, which integrates Copernicus satellite environmental data with patient-reported symptoms for predictive modeling of atopic dermatitis flare-ups. Nia Health operates a multi-stakeholder business model with three primary revenue streams: (1) B2B enterprise licensing, sponsorship, and co-development agreements with pharmaceutical companies including Sanofi, Pfizer, and LEO Pharma; (2) health insurance reimbursement agreements with major German statutory insurers (DAK-Gesundheit, KKH, AOK PLUS) collectively covering over 10 million insured members, where insurers pay for premium app access provided free to patients; and (3) digital trial companion services for clinical research. The company reported revenue more than doubled in 2022 versus 2021 and operates with a 18-20 person team.

Nia Health's go-to-market is hybrid: enterprise sales to pharma and insurers combined with B2C consumer app distribution through Google Play and Apple App Store channels. The company holds ISO 27001 certification and GDPR compliance, and its technology is currently used in at least five clinical studies including randomized controlled trials at Charité. With €3.5 million in seed funding raised in May 2023, Nia Health is positioned for European expansion within 24 months and US market preparation while continuing to build its indication-specific digital therapeutics pipeline (urticaria, chronic rhinosinusitis, and sunburn apps in development).

Name

Nia Health

Legal name

Nia Health GmbH

Website

https://nia-medtech.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Nia Health is a Berlin-based digital health company that develops CE-approved AI-powered medical device apps for chronic skin conditions including eczema, psoriasis, and acne, serving patients, dermatologists, pharmaceutical companies, and German statutory health insurers with technology for disease monitoring and digital therapy management.

Ownership category

akta.pro rank

Product category

Digital Health Applications (Digital Therapeutics / DiGA)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)

akta.pro industry

PRIMARYHLALAGAA

Dermatology Telemedicine Platforms

Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

SECONDARYHLACAPAB

Connected Medical Devices & Wearables (Sensors, Patches, Implantables)

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

• Digital therapeutics software
• Medical device apps
• Teledermatology solutions
• Chronic disease management
• AI health applications

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Health Insurance Reimbursement: Premium versions of apps (Nia, Sorea) reimbursed through partnerships with statutory health insurers including DAK-Gesundheit, KKH, and AOK PLUS. Patients receive free premium access; Nia Health receives payment from insurers.
2. B2B Enterprise Licensing: Licensing and partnership agreements with pharmaceutical companies (Sanofi, Pfizer, LEO Pharma) for digital therapy management, sponsorship, and co-development of digital health solutions.
3. Digital Trial Companion Services: Contract research services providing clinical trial digital support to pharmaceutical companies and academic institutions, collecting real-world evidence data.
4. Consumer Freemium Model: Free basic app functions with premium upgrade options for patients not covered by health insurance partnerships.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Nia Health develops CE-approved medical device software applications (Digital Therapeutics/DiGA) for patients with chronic skin conditions. The core product line consists of three patient-facing apps — Nia for atopic dermatitis/eczema, Sorea for psoriasis, and milderma for acne — which use machine vision, natural language processing, and teledermatology to document disease progression, identify environmental triggers, and facilitate patient-physician communication. The company also offers Remote Patient Monitoring and Digital Trial Companion services for healthcare providers and pharmaceutical sponsors.

Product overview

Nia Health develops a modular digital health platform for dermatology and allergology, combining CE-approved medical device apps with AI-powered analysis capabilities. The core portfolio includes three commercial products: Nia (atopic eczema app), Sorea (psoriasis app), and milderma (acne app) - all approved as medical devices. The platform integrates Remote Patient Monitoring and Digital Trial Companion modules for clinical support. Under development are additional apps for urticaria, chronic rhinosinusitis, and sunburn. The technology stack combines machine vision, natural language processing, and teledermatology. The ADEN platform extends capabilities by integrating environmental satellite data with patient-reported symptoms for predictive flare-up modeling.

Differentiator

Problem solved

Functional benefit

Brands

• Nia: Award-winning eczema/atopic dermatitis app - the most used medical eczema app in Europe, approved as a medical device in 2019
• Sorea
• milderma
• ADEN

Products and services

• Nia (Eczema App) CE-approved Class I medical device app for patients with atopic dermatitis (eczema). Enables photo documentation, clinically validated severity scoring (PO-SCORAD), symptom tracking, trigger identification, therapy adherence, and asynchronous doctor-patient communication. Targeted at eczema patients and their families; the most widely used medical eczema app in Europe.
• Sorea (Psoriasis App) CE-approved Class I medical device app for patients with psoriasis. Enables intelligent recording of skin appearance using textual and photographic records, pattern recognition during disease course, and clinically validated PASI-Score documentation. Used for objective tracking of psoriasis severity.
• milderma (Acne App) CE-approved Class I medical device app for patients with chronic acne. Digital companion developed with patients and key opinion leaders to support patients with chronic acne management.
• ADEN Platform AI platform that combines Copernicus Earth Observation satellite data (air pollution, UV radiation, pollen levels) with patient-reported symptoms to identify personal risk profiles and provide precise personalized forecasts for eczema flare-ups, enabling better prevention strategies.
• Remote Patient Monitoring (RPM) Service for clinicians that combines AI-based analysis of heterogeneous health, behavioral, and environmental data with expert medical knowledge to enable continuous patient monitoring, with automatic threshold-based alerts to physicians for reactive treatment adjustments independent of time and place.
• Digital Trial Companion Contract research service providing clinical trial digital support to pharmaceutical companies and academic institutions, collecting multiple data points including environmental factors, personal circumstances, and patient-reported outcomes to enable real-world evidence generation while improving participant compliance.

Quantifiable outcome

• More than doubled revenue in 2022 compared to 2021
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• University of Augsburg (Institute of Environmental Medicine)coreStrategic or Co-development Partner · 21 October 2024Collaboration on ADEN project combining Copernicus satellite data with patient data for personalized eczema flare-up prediction. Prof. Dr. Claudia Traidl-Hoffmann leads the institute. Project won €30,000 Cassini Challenge Award in 2025.
• EIT HealthminorStrategic or Co-development Partner · 6 June 2023EU institution supporting Nia Health with Headstart Award (€50,000) and ongoing network access to European industrial companies and investors in biotech, medtech, and digital health.
• Deutscher Psoriasis Bund e.V. (DPB)minorStrategic or Co-development Partner · 19 October 2022German psoriasis patient organization (founded 1973) supporting Sorea app development and patient education. Marius Grosser, DPB Managing Director, welcomed collaboration for advancing psoriasis care through modern digital tools.
• AOK PLUScoreStrategic or Co-development Partner · 3 December 2021Largest statutory health insurance in Saxony and Thuringia (3.4 million members) covering premium version costs for eczema app. Partnership positioned as milestone in reaching more people affected by atopic dermatitis.
• LEO PharmacoreStrategic or Co-development Partner · 28 October 2021Pharmaceutical cooperation partner focused on dermatological indications including atopic dermatitis. Expanded cooperation in December 2022 for digital therapy management of patients with moderate to severe AD. Dr. Marc A. Heim, Managing Director LEO Pharma Germany, views Nia Health as strong ally with patient-centered approach.
• PfizercoreStrategic or Co-development Partner · 14 September 2021New cooperation and sponsorship partnership for continued Nia app development. Dr. Karsten Graudenz, Managing Director Pfizer Pharma GmbH, sees digital care expansion as important step toward better quality, personalized medical care.
• Sanofi GenzymecoreStrategic or Co-development Partner · 31 March 2021Specialty Care Business Unit of Sanofi serves as sponsoring partner supporting the Nia app approved as class I medical device. Partnership extended twice since 2021. Focus on immunology and atopic dermatitis digital therapy management. Markus Isenmann, Franchise Head Immunology, cited partnership as shaping future of patient care.
• KKH Kaufmännische KrankenkassecoreStrategic or Co-development Partner · 1 November 2020Second major health insurance partner (1.7 million members) listing Eczema App Nia for free premium access to all insured members with eczema. Chairman Dr. Wolfgang Matz emphasized commitment to patient empowerment and direct exchange with members.
• DAK-GesundheitcoreStrategic or Co-development Partner · 1 July 2020Third-largest German health insurance company (5.6 million members) providing free Nia app premium access to insured members as first major NHI cooperation. Andreas Storm, CEO of DAK, sees app as important extension to existing eczema treatment methods using latest scientific findings.
• Charité Universitätsmedizin BerlincoreStrategic or Co-development Partner · 1 January 2019Founding institution and ongoing research partner. Nia Health originated as spin-off from Charité. Prof. Dr. med. Margitta Worm serves as Head of Allergology and Immunology at Charité and has conducted clinical studies demonstrating positive effects of Nia app on patient quality of life.
• Fachklinik Bad BentheimminorStrategic or Co-development Partner · 1 January 2019Clinical partner with PD Dr. med. Athanasios Tsianakas serving as Medical Director in Department of Dermatology. Provides clinical expertise for product development and validation.
• University Hospital ZurichminorStrategic or Co-development Partner · 1 January 2019Prof. Dr. med. Peter Schmid-Grendelmeier, Head Allergy Unit & Responsible for Education at Dept. of Dermatology, serves as Key Opinion Leader endorsing Nia Health technology and vision.
• AGNES e.V.minorStrategic or Co-development Partner · 1 January 2019Patient education organization whose curriculum forms basis for scientifically validated content in Nia and Sorea apps. Provides standardization and credibility for educational materials.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Kaia Health: Digital therapeutics company with AI-driven musculoskeletal and chronic disease management apps. Comparable in DTx business model, B2B payer/partnerships, and clinical evidence approach.
• OnlineDoctor: Swiss-German teledermatology platform enabling remote dermatologist consultations. Competes in DACH dermatology with similar B2C app model and health insurance reimbursement coverage.
• SkinVision: AI-based skin lesion assessment app using computer vision to evaluate skin conditions. Comparable in CE-marked AI dermatology technology and consumer/B2B2C distribution approach.
• Cara Care: Berlin-based digital health company for digestive conditions with CE-marked, DiGA-reimbursed DTx app. Comparable in German DTx regulatory pathway, condition-specific digital coaching, and B2B partnership model.
• dermanostic: German teledermatology service connecting patients to dermatologists via app-based photo consultations. Direct competitor in the German dermatology digital health space, with similar hybrid B2C/B2B motion and health insurance partnerships.
• Selfapy: Berlin-based digital therapeutics company offering DiGA-approved online courses for mental health conditions. Comparable in German DTx regulatory model, reimbursement partnerships, and B2C/B2B approach.
• Miiskin: Skin tracking and mole monitoring app used for dermatology documentation and teledermatology support. Comparable in smartphone-based skin imaging and digital disease tracking for chronic skin conditions.
• GAIA AG: Digital therapeutics pioneer with proven DTx products across multiple indications including mental health. Comparable in mature DTx platform model, clinical evidence generation, and pharma/B2B partnerships.
• HelloBetter: German digital therapeutics company with CE-marked and DiGA-approved psychotherapeutic apps reimbursed by statutory health insurers. Comparable in DTx regulatory pathway, German payer model, and clinical evidence approach.

Broad incumbents

• Doctolib: European leader in online doctor appointment booking and telehealth. Overlap in digital health distribution to German patients and providers but operates as broad incumbent rather than dermatology specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/nia_helferin
• LinkedInlinkedin.com/company/digitale-helferin
• Facebookfacebook.com/MyHealthCompanion

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nia Health